Los Angeles, CA. Nixon Peabody advised Canadian in vitro diagnostics company Metabolomic Technologies Inc. (MTI) on the U.S. expansion of its groundbreaking test, PolypDx™, which detects precancerous adenomatous polyps and helps prevent colorectal cancer.

As the first and only urine-based adenomatous polyp screening test, this proprietary, non-invasive test is a transformative advancement in the fight against colorectal cancer. According to the American Cancer Society, nearly 150,000 people will be diagnosed with colorectal cancer in 2020, and more than 50,000 will die as a result. Lack of early screening has been cited as one of the largest contributing factors to the increase in cases and unfavorable patient outcomes.

The expansion of PolypDx™ eliminates many of the access-to-health-care barriers and inconveniences associated with tests that require bowel cleansing preparation or insanitary handling of stool. The breakthrough test provides an increased number of patients across the country with access to critical early screening. Through strategic partnerships, MTI will offer a simple home sample collection kit paired with access to a national telehealth network for patient consultations.

“It was an honor working closely with MTI on the milestone expansion of PolypDx™ at-home testing kits across the U.S. market,” said Nixon Peabody Health Care senior associate Harsh Parikh, who led the firm’s team advising MTI. “We look forward to continuing to support MTI and its mission to make life-saving early detection of precancerous adenomatous polyps available to everyone.”

Nixon Peabody worked with MTI in connection with its U.S. strategy, including the set-up of a national telehealth network, website privacy policies, HIPPA regulations, and laboratory partnerships. In addition to Parikh, the firm’s team included Jill Gordon, Health Care partner and co-chair of the Life Sciences practice, Health Care partners Valerie Montague and Rebecca Simone, and associates Alexandra Busto and Jennifer Greco.

For further information, see the press release: First & Only Urine Test for Colon Polyps Expands Across the US.